Nat. Rev. Rheumatol. doi: /nrrheum

Slides:

Advertisements

Similar presentations

Disease Modifying Anti-Rheumatic Drugs (DMARDs) Immunomodulatory and immunosuppresive Xenobiotic – Gold salts – Azathioprine – Methotrexate Biological.

Advertisements

NSAIDs 1 st line of therapy in the medical management of RA.

Can Rheumatoid Arthritis treatment ever be stopped? Robert L. DiGiovanni, DO, FACOI Program Director Largo Medical Center Rheumatology Fellowship

Which of the following cells are involved in the pathogenesis of rheumatoid arthritis? 1.B cell 2.T cell 3.Macrophage 4.All of above.

DR.IBTISAM JALI MEDICAL DEMONSTRATOR

Rheumatoid Arthritis Dr Chandini Rao Consultant Rheumatologist.

Planning for Biosimilars: Infliximab Professor Ray Fitzpatrick Secondary Care lead Keele University Clinical Director of Pharmacy Royal Wolverhampton NHS.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2013 update Smolen.

Failure of 2 standard DMARDs including MTX for 6 months DAS28 > 5.1 on 2 occasions 1 month apart TOLERANT MTX Choose most appropriate agent and if no clear.

Pearls and Practical Considerations for Biologic Agents

BIOLOGICS IN RHEUMATIC DISEASES – UPDATE 2017

A NEW LOOK AT RA Interactive Hot Topics Series

Rheumatoid arthritis The Lancet

New Treatments for Rheumatoid Arthritis

My Treatment Approach to Rheumatoid Arthritis

Recommendations for the treatment of established RA (disease duration 6 month or longer). Biologic, biological originator DMARD or boDMARD; DMARD, disease-modifying.

Prediction of Response to Targeted Treatment in Rheumatoid Arthritis

Nat. Rev. Rheumatol. doi: /nrrheum

Drug Therapy of Rheumatoid Arthritis

Anne Barton Professor of Rheumatology

Rheumatology for the GP

Clinical Developments in Inflammatory Arthritis 2017

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Introduction/Background

Introducing JAK Inhibitors in Rheumatoid Arthritis

Figure 1 Historical evolution of the clinical classification and

Figure 2 A timeline summarizing the development of diagnostic tools in rheumatology Figure 2 | A timeline summarizing the development of diagnostic tools.

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

From Conference to Practice: Big Data in Psoriasis

Figure 1 Structure of TNF antagonists

My Treatment Approach to Rheumatoid Arthritis

Figure 4 Simplified T cell and antigen presenting

Novel Small Molecule Therapies in Rheumatoid Arthritis

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Targeted versus untargeted metabolomics approaches

Clinical Updates in RA: New Developments and Insights From Washington

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Simplified EULAR and GRAPPA

Figure 2 Simplified EULAR and GRAPPA

Figure 3 Transcriptome studies performed in the target

Figure 2 Shared genetic loci in systemic autoimmune diseases

Figure 1 Location of HLA variants known to be associated

Nat. Rev. Rheumatol. doi: /nrrheum

What’s new in my specialty- Rheumatoid Arthritis

Figure 3 Strategies to achieve therapeutic inhibition of IL-1

Figure 2 Overlap of associated loci among five rheumatic diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Statistical approaches for the analysis of metabolomic data

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Simplified EULAR and GRAPPA

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Viewpoints of Practicing Rheumatologists: Case Discussions in RA

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 6 Metabolism of pterins

Mean change from baseline CDAI in abatacept and TNFi initiators with a typical patient profile. Mean change from baseline CDAI in abatacept and TNFi initiators.

Rheumatoid Arthiritis

Figure 1 Patterns of joint and organ involvement in rheumatic disease

Switching of biological agents (BAs), and achievement of inactive disease and clinical remission (CR). Switching of biological agents (BAs), and achievement.

Figure 1 The role of macrophages in RA

Patient-reported adherence towards different IMID treatments in RA (A), PsA (B) or AS (C). Patient-reported adherence towards different IMID treatments.

Patients with RA on csDMARDs with and without GC, bDMARDs/tofacitinib with and without GC on the x axis. Patients with RA on csDMARDs with and without.

Rheumatoid Arthritis.

Design for the long-term extension study RA-BEYOND from randomisation in the originating studies. Design for the long-term extension study RA-BEYOND from.

Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Suggested therapeutic management according to subtypes and severity of rheumatic immune-related adverse events (irAE). *Add-on therapy with DMARDs (disease-modifying.

Presentation transcript:

Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2017.95 Figure 1 A timeline summarizing the evolution of treatment for rheumatoid arthritis Figure 1 | A timeline summarizing the evolution of treatment for rheumatoid arthritis. Injectable gold salts were among the earliest treatments for rheumatoid arthritis (RA); an oral gold compound (auranofin) is also available. Glucocorticoids have been widely used in the treatment of RA since the 1950s, and methotrexate since the 1980s.The first TNF inhibitor, etanercept, was approved for use in RA in 1998; further anti-TNF agents (infliximab, adalimumab, certolizumab and golimumab) soon followed. Other biologic DMARDs include agents that target B cells (rituximab), co-stimulatory molecules (abatacept), IL-6 (tocilizumab, sarilumab) and IL-1 (anakinra). Apremilast is a PDE4 inhibitor. Tofacitinib is the first-in-class Janus kinase inhibitor for the treatment of RA, followed by baricitinib. csDMARD, conventional synthetic DMARD; tsDMARD, targeted synthetic DMARD. Burmester, G. K. et al. (2017) Managing rheumatic and musculoskeletal diseases — past, present and future Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2017.95